[6] In total, 26 patients with HCV genotype 2 (23 were treated) and 26 patients with HCV genotype 3 infection were randomly assigned to receive 15 days of telaprevir, telaprevir plus peginterferon/
ribavirin, or peginterferon/
ribavirin, all followed by peginterferon/
ribavirin for 22-24 weeks.
Unfortunately, the results of this study were somewhat disappointing. There was additive efficacy with telaprevir in patients with HCV genotype 2 infection.